Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent

Granules India Q1 FY26 PAT slips to Rs. 112.6 Cr

Briefs: Nectar Lifesciences, Cipla and Marksans Pharma

Marksans Pharma gets USFDA nod for acid reflux drug

Centrient Pharmaceuticals joins UNGC

Reinforcing commitment to ethical and sustainable growth

Boehringer’s lung cancer medicine gets FDA approval

FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC

Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA

Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India

Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

AINU is set to accelerate its expansion footprint, enhance operational capabilities

Sandoz launches renewable energy partnership

The agreement complements other PPAs for Sandoz production sites globally

Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp